Arthritis Res Ther 2018 DOI: 10.1186/s13075-018-1544-9 View full text
|
|
Share
James Bluett, Jamie C. Sergeant, Alex J. MacGregor, Jacqueline R. Chipping, Tarnya Marshall, Deborah P. M. Symmons, Suzanne M. M. Verstappen

Abstract: BackgroundOral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA). However, approximately one quarter of patients discontinue MTX within 12 months. MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse event(s) and/or inefficacy. The aims of this study were to evaluate the rate and predictors of oral MTX failure.MethodsSubjects were recruited from the Norfolk Arthritis Register (NOAR), a primary care-based inception co…

expand abstract